Monographie - Folinate calcium

Última actualização :
19/11/2024

Folinate calcium

estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Antrex	Finlandia
Axifolin	Alemanha
Bendafolin	Egipto, Irã
Biofolic	Itália
Calcium leucovorin	Turquia
Calfolex	Itália
Citofolin	Itália
Cromaton	Luxemburgo
Dalisol	Colômbia, Índia, México
Degalin	Alemanha
Durofolin	Grècia
Etamolin	Peru
Eurofolic	Alemanha
Fastovorin	Índia
Folcasin	Romènia
Folical	Colômbia
Folidan	Espanha
Folinate de calcium	França
Furoic	Itália
Innefol	México
Lederfolin	Gran-bretanha, Irlanda, Itália
Ledervorin calcium	Arábia Saudita, Australia, Bélgica, Colômbia, Emirados Árabes Unidos, Irlanda, Luxemburgo, Polonia
Leucocalcin	Argentina, Chilli
Leucovorin	Alemanha, Austria, Bélgica, Eslovenia, Gran-bretanha, Grècia, Hungria, Polonia, Suicia, Turquia
Neofolin	Alemanha
Novizet	Argentina
Precileucin	México
Prefolic	Itália
Refolinon	Gran-bretanha, Grècia
Rescuvolin	Africa do sul, Alemanha, Bélgica, Colômbia, Grècia, Luxemburgo, Malásia, Países Baixos, Suècia
Ribofolin	Alemanha, Austria, Irã
Rontafor	Argentina
Sanficinate	Grècia
Sanifolin	Itália
Tecnovorin	Colômbia, Peru
Veravorin	Grècia
Xanacanto	México

Bibliografía : Folinate calcium

	tipo	publicação
73	jornal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	jornal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
99	jornal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	jornal	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
155	jornal	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
182	jornal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	jornal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	jornal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	jornal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	jornal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479	jornal	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	jornal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
763	jornal	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
905	jornal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	jornal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1287	jornal	Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991 ; 53: 90-94.
1410	jornal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	jornal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	jornal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	jornal	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	jornal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	jornal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	jornal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1914	Laboratório	Pemetrexed (Alimta®) - Summary of Product Characteristics Eli Lilly 2016
1925	jornal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	jornal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	jornal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027	jornal	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2130	jornal	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	jornal	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2295	Laboratório	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2340	jornal	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474	Laboratório	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3523	Laboratório	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3546	Laboratório	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3619	Laboratório	Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics Wockhardt 2016
3621	Laboratório	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3634	Laboratório	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3694	jornal	Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 1989 ; 46: 985-989.
3753	Laboratório	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3838	Laboratório	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3933	Laboratório	Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit Teva Laboratoire 2015
4154	Laboratório	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4720	Laboratório	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021

Mentions Légales